6.1.1.2 | proteolytic modification |
regulated mechanism, the C-terminal domain of the enzyme, which has anti-angiogenic activity and inhibits immune cells, is isolated by proteolytic cleavage or alternative splicing, the mini enzyme is a potent inhibitor of blood vessel development, the full-length enzyme is inactive, enzyme N-terminally processed by elastase, resulting in 2 different forms T1 and T2, has also anti-angiogenic activity |
650116 |